Humanigen Appoints Senior Executives to Management Team

July 7, 2020

First Patient Infused in Joint Humanigen/Kite, A Gilead Company Clinical Study

June 30, 2020

Humanigen Reports Additional Analysis of Lenzilumab in Severe and Critical COVID-19 Patients

June 16, 2020

Mayo Clinic Study of Humanigen’s Lenzilumab Shows Rapid Recovery and Discharge in Severe and Critical COVID-19 Patients

June 15, 2020

Humanigen Announces $71,800,000 Equity Financing

June 2, 2020

First Patient Dosed in FDA-Approved Phase III Lenzilumab Study for COVID-19

May 6, 2020

FDA Approves Initiation of Humanigen’s Phase III Study of Lenzilumab in COVID-19 Patients

April 15, 2020

FDA Approves Emergency IND Use of Humanigen’s Lenzilumab for Compassionate Use in COVID-19 Patients

April 2, 2020

Humanigen Partners With CTI, A Leading Contract Research Organization, For Planned Phase III Study For Lenzilumab For Coronavirus Treatment

March 30, 2020

Humanigen Submits Phase III Protocol Synopsis to FDA for Lenzilumab for Coronavirus Treatment

March 27, 2020

  • Twitter

©2020 Humanigen, Inc.  All rights reserved